Страна: Канада
Език: английски
Източник: Health Canada
CITALOPRAM (CITALOPRAM HYDROBROMIDE)
MINT PHARMACEUTICALS INC
N06AB04
CITALOPRAM
40MG
TABLET
CITALOPRAM (CITALOPRAM HYDROBROMIDE) 40MG
ORAL
30/100
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0136243002; AHFS:
APPROVED
2014-09-05
_MINT-CITALOPRAM Product Monograph_ Page 1 of 45 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MINT-CITALOPRAM Citalopram Tablets Tablets, 10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide), Oral USP Antidepressant Mint Pharmaceuticals Inc. Date of Initial Authorization: 6575 Davand Drive September 5, 2014 Mississauga, Ontario L5T 2M3 Date of Revision: February 28, 2024 SUBMISSION CONTROL NUMBER: 279156 Page 2 of 45 _MINT-CITALOPRAM Product Monograph_ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 02/2024 7 WARNINGS AND PRECAUTIONS, Hematologic 07/2022 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 07/2022 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 07/2022 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ....................................................................................................... 2 TABLE OF CONTENTS ....................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................ 4 1 INDICATIONS .............................................................................................................................. ….4 1.1 Pediatrics ........................................................................................................................ 4 1.2 Geriatrics ........................................................................................................................ 4 2 CONTRAINDICATIONS .................................................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS .................................................................................. 5 4 DOSAGE AND ADMINISTRATION ............................................................................................. Прочетете целия документ